drugset / Trial / NCT03352869

Research of Exenatide for Overweight/Obese PCOS Patients With IGR

NCT03352869

Phase 4 Completed 183 enrolled RenJi Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

Compare the therapeutic effects of exenatide, metformin and their combination for 3 months on reproductive and metabolic improvements of overweight/obese PCOS patients with impaired glucose regulation.

Timeline

Start
2017-11-28
Primary completion
2018-07-01
Completion
2018-07-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 10 ug
Subject Exenatide Peptide 20 ug
Subject Metformin Small molecule 1500 mg
Subject Metformin Small molecule 2000 mg